Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For more information, visit "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. Artificial Intelligence for Digital Breast Tomosynthesis – Reader Study Results. Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. For more information, visit References:ġ.) Conant, E. ProFound AI for 2D Mammography was CE marked in July 2019. ProFound AI for DBT was FDA-cleared, CE marked, and Health Canada licensed in 2018. ICAD will also be hosting a symposium during the JFR congress, titled “AI- The New Partner for Radiologists in Breast Cancer Detection” on Sunday, October 13, at 12:30 in Conference Room #251, featuring Dr. “In the beginning, I was skeptical about how AI could help me, but I quickly understood the undeniable assistance ProFound AI could bring, especially with subtle lesions and complex cases.”
I use ProFound AI in my daily practice, and it helps me in my diagnostic decision making,” said Corinne Balleyguier, MD, PhD, radiologist at Gustave Roussy Cancer Campus, Villejuif, France. “The arrival of ProFound AI marks a real technological advancement in the development of breast cancer detection tools. 1 Additionally, ProFound AI cut reading time by up to 57.4 percent for radiologists reading cases with dense breasts.
According to the study, ProFound AI for DBT improved radiologist sensitivity by 8 percent, reduced unnecessary patient recall rates by 7.2 percent, and slashed reading time for radiologists by 52.7 percent.
Positive clinical data from a large reader study involving ProFound AI for DBT were recently published in Radiology: Artificial Intelligence. It also features the latest in deep-learning artificial intelligence, which allows for continuously improved performance via ongoing updates.
#Icad paris software
Trained with one of the largest available datasets, the software is designed to rapidly and accurately analyze each image and provide radiologists with key information, such as Certainty of Finding lesion and Case Scores, which assists in clinical decision-making and prioritizing caseloads. ProFound AI for 2D Mammography and ProFound AI for DBT are high-performing workflow solutions featuring the latest in deep-learning artificial intelligence capabilities. “This revolutionary technology improves radiologists’ confidence and optimizes workflow and operational efficiencies, even with the most challenging cases to read, such as those with dense breasts.” Its use continues to increase in France, as well as a growing number of countries worldwide, as more clinicians discover the benefits it offers,” said Michael Klein, Chairman and CEO of iCAD. “ProFound AI for DBT is the first and only artificial intelligence software for DBT that is clinically proven to enhance breast cancer screening, reduce false positives and unnecessary recalls, and cut reading time for radiologists by more than half.
The ProFound AI Platform includes both ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE marked in March 2018 and FDA cleared in December 2018, as well as ProFound AI™ for 2D Mammography, which was CE marked in July 2019.
#Icad paris full
(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the full ProFound AI™ platform will be featured in the iCAD exhibition booth (#226A) at the Journées Francophones de Radiologie (JFR) Congress in Paris from October 11-14, 2019.
0 kommentar(er)
